Kava (piper methysticum): Complementary therapies, herbs, and other otc agents

Oncology

Volumn 25, Issue 4, 2011, Pages

  Cassileth, Barrie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; IPSAPIRONE; KAVA; KAVALACTONE; KAWAIN; NON PRESCRIPTION DRUG; PLACEBO; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; ANXIETY DISORDER; AQUEOUS SOLUTION; ARTICLE; ATAXIA; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; HERBAL MEDICINE; HUMAN; INSOMNIA; LIVER INJURY; LIVER TOXICITY; MENOPAUSAL SYNDROME; MENTAL DISEASE; NONHUMAN; PIPER METHYSTICUM; RASH; SKIN DISEASE; URINARY TRACT INFECTION; URTICARIA;

EID: 79956192297     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lim ST, Dragull K, Tang CS, et al. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci. 2007; 97 214-21.
2. Lude S, Torok M, Dieterle S, et al. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine. 2008; 15: 120-31.
3. Hoover JM, Kaye AD, Ibrahim IN, et al. Analysis of responses to kava kava in the feline pulmonary vascular bed. J Med Food. 2006; 9: 62-71.
4. Grunze H, Langosch J, Schirrmacher K, et al. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar to established mood stabilizersa review. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25: 1555-70.
5. Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J. 2000; 59: 420-2.
6. Matsuda H, Hirata N, Kawaguchi Y, et al. Melanogenesis stimulation in murine B16 melanoma cells by Kava (Piper methysticum) rhizome extract and kavalactones. Biol Pharm Bull. 2006; 2: 834-7.
7. Ernst E. Herbal remedies for anxietya systematic review of controlled clinical trials. Phytomedicine. 2006; 13: 205-8.
8. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res. 2005; 19: 183-8.
9. Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ. Jan 20 2001; 322: 139.
10. Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett. 2004; 150: 85-96.
11. Raman P, Dewitt DL, Nair MG. Lipid peroxidation and cyclooxygenase enzyme inhibitory activities of acidic aqueous extracts of some dietary supplements. Phytother Res. Feb 2008; 22: 204-212.
12. Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl). 2009; 205: 399-407.
13. Singh YN, Devkota AK. Aqueous kava extracts do not affect liver function tests in rats. Planta Med. 2003; 69: 496-9.
14. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int. 2010; 30: 1270-9.
15. Christl SU, Seifert A, Seeler D. Toxic hepatitis after consumption of traditional kava preparation. J Travel Med. 2009; 16: 55-6.
16. Grace R. Kava-induced urticaria. J Am Acad Dermatol. 2005; 53: 906.
17. Perez J, Holmes JF. Altered mental status and ataxia secondary to acute Kava ingestion. J Emerg Med. 2005; 28: 49-51.
18. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol. 1994; 31: 89-97.
19. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996; 125: 940-1.
20. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005; 77: 415-26.
21. Russmann S, Lauterburg BH, Barguil Y, et al. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? Clin Pharmacol Ther. 2005; 77: 453-4.
22. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med. 2001; 135: 68-9.
23. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001; 286: 208-16.